The implications of the findings of these studies are that SGLT2 inhibitors appear to reduce the risk of hospitalization for HF in patients both without a pre-existing diagnosis of HF and in those with established HF; applicable for non-diabetic patients and those with T2D. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.